Clinicopathologic features of TDO2 overexpression in renal cell carcinoma.
Cancer stem cell
PD-L1
PTEN
Renal cell carcinoma
TDO2
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
26 Jun 2021
26 Jun 2021
Historique:
received:
27
01
2021
accepted:
24
05
2021
entrez:
27
6
2021
pubmed:
28
6
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Tryptophan 2,3-dioxygenase (TDO2) is the primary enzyme catabolizing tryptophan. Several lines of evidence revealed that overexpression of TDO2 is involved in anoikis resistance, spheroid formation, proliferation, and invasion and correlates with poor prognosis in some cancers. The aim of this research was to uncover the expression and biofunction of TDO2 in renal cell carcinoma (RCC). To show the expression of TDO2 in RCC, we performed qRT-PCR and immunohistochemistry in integration with TCGA data analysis. The interaction of TDO2 with PD-L1, CD44, PTEN, and TDO2 expression was evaluated. We explored proliferation, colony formation, and invasion in RCC cells line affected by knockdown of TDO2. RNA-Seq and immunohistochemical analysis showed that TDO2 expression was upregulated in RCC tissues and was associated with advanced disease and poor survival of RCC patients. Furthermore, TDO2 was co-expressed with PD-L1 and CD44. In silico analysis and in vitro knockout of PTEN in RCC cell lines revealed the ability of PTEN to regulate the expression of TDO2. Knockdown of TDO2 suppressed the proliferation and invasion of RCC cells. Our results suggest that TDO2 might have an important role in disease progression and could be a promising marker for targeted therapy in RCC. (199 words).
Sections du résumé
BACKGROUND
BACKGROUND
Tryptophan 2,3-dioxygenase (TDO2) is the primary enzyme catabolizing tryptophan. Several lines of evidence revealed that overexpression of TDO2 is involved in anoikis resistance, spheroid formation, proliferation, and invasion and correlates with poor prognosis in some cancers. The aim of this research was to uncover the expression and biofunction of TDO2 in renal cell carcinoma (RCC).
METHODS
METHODS
To show the expression of TDO2 in RCC, we performed qRT-PCR and immunohistochemistry in integration with TCGA data analysis. The interaction of TDO2 with PD-L1, CD44, PTEN, and TDO2 expression was evaluated. We explored proliferation, colony formation, and invasion in RCC cells line affected by knockdown of TDO2.
RESULTS
RESULTS
RNA-Seq and immunohistochemical analysis showed that TDO2 expression was upregulated in RCC tissues and was associated with advanced disease and poor survival of RCC patients. Furthermore, TDO2 was co-expressed with PD-L1 and CD44. In silico analysis and in vitro knockout of PTEN in RCC cell lines revealed the ability of PTEN to regulate the expression of TDO2. Knockdown of TDO2 suppressed the proliferation and invasion of RCC cells.
CONCLUSION
CONCLUSIONS
Our results suggest that TDO2 might have an important role in disease progression and could be a promising marker for targeted therapy in RCC. (199 words).
Identifiants
pubmed: 34174844
doi: 10.1186/s12885-021-08477-1
pii: 10.1186/s12885-021-08477-1
pmc: PMC8236178
doi:
Substances chimiques
Biomarkers, Tumor
0
Tryptophan Oxygenase
EC 1.13.11.11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
737Références
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
FEBS J. 2010 Jan;277(2):316-26
pubmed: 19922467
Cancer Cell. 2014 Sep 8;26(3):319-330
pubmed: 25155756
World J Urol. 2016 Aug;34(8):1081-6
pubmed: 26847337
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Cancer Res. 2012 Nov 1;72(21):5435-40
pubmed: 23090118
Blood. 2008 Jan 1;111(1):112-21
pubmed: 17890457
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502
pubmed: 22308364
Int J Tryptophan Res. 2017 Mar 15;10:1178646917691938
pubmed: 28469468
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Anticancer Res. 2017 Jun;37(6):2853-2860
pubmed: 28551621
Front Oncol. 2020 Oct 15;10:583228
pubmed: 33178611
Int J Cancer. 1993 Jan 2;53(1):36-41
pubmed: 8416202
Sci Rep. 2020 Apr 6;10(1):5955
pubmed: 32249812
Cancer Res. 2015 Nov 1;75(21):4651-64
pubmed: 26363006
Front Immunol. 2020 May 14;11:657
pubmed: 32477324
Clin Cancer Res. 2018 Mar 1;24(5):1227-1239
pubmed: 29229632
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Nature. 2011 Oct 05;478(7368):197-203
pubmed: 21976023
Front Oncol. 2019 Aug 23;9:800
pubmed: 31508364
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Oncology. 2018;95(5):297-308
pubmed: 30134247
Cancer Cell. 2020 Dec 14;38(6):803-817.e4
pubmed: 33157048
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
J Cancer Res Clin Oncol. 2020 Dec;146(12):3155-3163
pubmed: 32776284
Cancers (Basel). 2019 Mar 28;11(4):
pubmed: 30925702
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Cancer Sci. 2020 Mar;111(3):1020-1027
pubmed: 31912588
Oncotarget. 2016 Oct 11;7(41):66540-66557
pubmed: 27572319
Anticancer Res. 2020 Apr;40(4):1943-1951
pubmed: 32234883
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230